States, Global Power and Access to Medicines: a Comparative Case Study of China, India and the United States, 2000-2019

Overview

Journal Global Health

Publisher Biomed Central

Date 2025 Feb 1

PMID 39893431

Authors

Berit S H Hembre

Maulik Chokshi

Steven J Hoffman

Fatima Suleman

Steinar Andresen

Kristin Sandberg

John-Arne Rottingen

Affiliations

Soon will be listed here.

Abstract

Background: What constitutes state`s global power to shape access to medicines? How was it distributed between states and how did this change from 2000 to 2019? In this comparative case study, we explored the powers of China, India and the United States, and discuss whether our findings from the pre-pandemic era were reflected in the global COVID-19 response related to pharmaceuticals. We used an analytical framework from the international relations literature on structural power, and assessed the following power structures after adapting them to the context of access to medicines: finance, production, financial protection, knowledge, trade and official development assistance.

Results: We found that from 2000 to 2019 there had been a power-shift towards China and India in terms of finance and production of pharmaceuticals, and that in particular China had increased its powers regarding knowledge and financial protection and reimbursement. The United States remained powerful in terms of finance and knowledge. The data on trade and official development assistance indicate an increasingly powerful China also within these structures. During the COVID-19 pandemic, we found that the patterns from previous decades were continued in terms of cutting-edge innovation coming out of the United States. Trade restrictions from the United States and India contrasted our findings as well as the limited effective aid from the United States. Building on our findings on structural powers, we argue that both structural power and political decisions shaped access to medical technologies during the COVID-19 pandemic. We also examined the roles and positions of the three states regarding developments in global health governance on the COVAX mechanism, the TRIPS Agreement waiver and the pandemic accord in this context.

Conclusion: From 2000-2019, China and India increased their structural powers to shape global access to medical technologies. The recent COVID-19 pandemic demonstrated that both structural power and political decisions shaped global access to COVID-19 technologies.

References

Himmelstein D, Thorne D, Warren E, Woolhandler S . Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009; 122(8):741-6. DOI: 10.1016/j.amjmed.2009.04.012. View

Chattu V, Singh B, Kaur J, Jakovljevic M . COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform. Biomed Res Int. 2021; 2021:6658070. PMC: 8416375. DOI: 10.1155/2021/6658070. View

Ahlin T, Nichter M, Pillai G . Health insurance in India: what do we know and why is ethnographic research needed. Anthropol Med. 2016; 23(1):102-24. DOI: 10.1080/13648470.2015.1135787. View

Chen J, Nie X, Yao P, Shi L . TRIPS-plus and access to medicines in China. J Public Health Policy. 2013; 34(2):226-38. PMC: 7099318. DOI: 10.1057/jphp.2013.13. View

Li J, Qin S, Xu R, Shen L, Xu J, Bai Y . Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018; 319(24):2486-2496. PMC: 6583690. DOI: 10.1001/jama.2018.7855. View

Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K . Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med. 2016; 13(5):e1002032. PMC: 4886962. DOI: 10.1371/journal.pmed.1002032. View

Rottingen J, Regmi S, Eide M, Young A, Viergever R, Ardal C . Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?. Lancet. 2013; 382(9900):1286-307. DOI: 10.1016/S0140-6736(13)61046-6. View

Watt N, Gomez E, Mckee M . Global health in foreign policy--and foreign policy in health? Evidence from the BRICS. Health Policy Plan. 2013; 29(6):763-73. DOI: 10.1093/heapol/czt063. View

Haugen H . Does TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) prevent COVID-19 vaccines as a global public good?. J World Intellect Prop. 2021; 24(3-4):195-220. PMC: 8250901. DOI: 10.1111/jwip.12187. View

10.

Gostin L, Moon S, Meier B . Reimagining Global Health Governance in the Age of COVID-19. Am J Public Health. 2020; 110(11):1615-1619. PMC: 7542258. DOI: 10.2105/AJPH.2020.305933. View

11.

Stein F . Risky business: COVAX and the financialization of global vaccine equity. Global Health. 2021; 17(1):112. PMC: 8451387. DOI: 10.1186/s12992-021-00763-8. View

12.

Griffith K, Jones D, Bor J, Sommers B . Changes In Health Insurance Coverage, Access To Care, And Income-Based Disparities Among US Adults, 2011-17. Health Aff (Millwood). 2020; 39(2):319-326. PMC: 8139823. DOI: 10.1377/hlthaff.2019.00904. View

13.

Wagstaff A, Flores G, Hsu J, Smitz M, Chepynoga K, Buisman L . Progress on catastrophic health spending in 133 countries: a retrospective observational study. Lancet Glob Health. 2017; 6(2):e169-e179. DOI: 10.1016/S2214-109X(17)30429-1. View

14.

Waning B, Diedrichsen E, Moon S . A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc. 2010; 13:35. PMC: 2944814. DOI: 10.1186/1758-2652-13-35. View

15.

Schaefer G, Atuire C, Kaur S, Parker M, Persad G, Smith M . The importance of getting the ethics right in a pandemic treaty. Lancet Infect Dis. 2023; 23(11):e489-e496. DOI: 10.1016/S1473-3099(23)00364-X. View

16.

Hu Y, Scherngell T, Man S, Wang Y . Is the United States still dominant in the global pharmaceutical innovation network?. PLoS One. 2013; 8(11):e77247. PMC: 3818371. DOI: 10.1371/journal.pone.0077247. View

17.

Fajber K . Business as Usual? Centering Human Rights to Advance Global COVID-19 Vaccine Equity Through COVAX. Health Hum Rights. 2022; 24(2):219-228. PMC: 9790946. View

18.

Rodwin V, Fabre G, Ayoub R . BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management. Int J Health Policy Manag. 2018; 7(3):201-206. PMC: 5890064. DOI: 10.15171/ijhpm.2017.145. View

19.

Usher A . A beautiful idea: how COVAX has fallen short. Lancet. 2021; 397(10292):2322-2325. PMC: 8494620. DOI: 10.1016/S0140-6736(21)01367-2. View

20.

Wirtz V, Hogerzeil H, Gray A, Bigdeli M, de Joncheere C, Ewen M . Essential medicines for universal health coverage. Lancet. 2016; 389(10067):403-476. PMC: 7159295. DOI: 10.1016/S0140-6736(16)31599-9. View